New combo therapy for lung cancer shows promise in early trial
NCT ID NCT03237377
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 28 times
Summary
This study tested giving immunotherapy drugs (durvalumab with or without tremelimumab) along with standard radiation before surgery for stage III non-small cell lung cancer. The goal was to see if this approach is safe and does not delay planned surgery. Only 9 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, 21224, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Conditions
Explore the condition pages connected to this study.